1.18
+0.01(+0.85%)
Currency In USD
| Previous Close | 1.17 |
| Open | 1.2 |
| Day High | 1.2 |
| Day Low | 1.16 |
| 52-Week High | 3.19 |
| 52-Week Low | 1.15 |
| Volume | 75,908 |
| Average Volume | 115,028 |
| Market Cap | 43.37M |
| PE | -1.36 |
| EPS | -0.87 |
| Moving Average 50 Days | 1.3 |
| Moving Average 200 Days | 1.57 |
| Change | 0.01 |
If you invested $1000 in Rafael Holdings, Inc. (RFL) since IPO date, it would be worth $240.82 as of December 24, 2025 at a share price of $1.18. Whereas If you bought $1000 worth of Rafael Holdings, Inc. (RFL) shares 5 years ago, it would be worth $48.78 as of December 24, 2025 at a share price of $1.18.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Rafael Holdings Mourns the Passing of Lead Independent Director, Stephen Greenberg, and Announces the Appointment of Alan Grayson to its Board of Directors
GlobeNewswire Inc.
Oct 28, 2025 8:01 PM GMT
NEWARK, N.J., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL; NYSE American: RFL-WT) sadly announced today the passing of its Lead Independent Director, Stephen Greenberg, and the appointment of Alan Grayson to its Board of Dire
Rafael Holdings Announces Presentation of Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label, Single-Arm Sub-Study in Patients Less Than 3 Years Old
GlobeNewswire Inc.
Sep 16, 2025 12:00 PM GMT
First data on treatment of NPC1 with Trappsol® Cyclo™ (hydroxypropyl-beta-cyclodextrin) in this age group over a period of 48 weeks At 48 weeks of the sub-study, 7 of 9 patients1 showed stabilization or improvement in CGI-S score Data presented at th
Rafael Holdings Announces Abstracts Accepted for Oral and Poster Presentations at the 15th International Congress of Inborn Errors of Metabolism (ICIEM)
GlobeNewswire Inc.
Aug 27, 2025 12:00 PM GMT
NEWARK, N.J., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL; NYSE American: RFL-WT) announced today that its subsidiary Cyclo Therapeutics has had two abstracts selected for presentation from its programs evaluating Trappsol® C